**Study Summary**: This study is about a new treatment called **ALT001** for people with a condition called **Multiple System Atrophy-Cerebellar type (MSA-C)**, which affects how the brain controls movements and balance. MSA-C is a rare and progressive disease that worsens over time, causing people to need walking aids or wheelchairs. The study will check if ALT001 is safe and if it helps improve symptoms. ALT001 is a special protein that might repair nerve damage.
**Study Details**:
- **Participants**: 20 patients with MSA-C, aged 30-75.
- **Duration**: The study lasts for 165 days, including follow-ups.
- **Procedures**: Includes blood tests, brain scans (MRI), and various health assessments.
**Considerations**:
- Participation involves regular hospital visits for tests and monitoring.
- The study aims to improve quality of life and slow disease progression.
- Participants must meet specific health criteria and agree to the study terms.
**Eligibility**: Must be diagnosed with MSA-C and meet specific health requirements. Those with other serious health conditions or who are pregnant cannot participate.
How understandable was the trial content above?
Hard to understand
Easy to understand